Company Profile
Alnylam Pharmaceuticals, Inc. Stock Price, News & Analysis
Company overview
Business overview
Alnylam Pharmaceuticals is an RNA medicines company focused on gene-silencing therapeutics across rare and specialty diseases. Investors watch platform execution, label expansion, and how new programs broaden the franchise.
Geographic Base and Sector Classification
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Alnylam is followed within the RNA therapeutics universe for its exposure to specialty-disease catalysts and platform growth.
Business Model Characteristics
Alnylam combines commercial execution with platform development, so the market focuses on launch momentum, pipeline depth, and how efficiently the company turns RNA science into growth.
Position Within the Biotechnology Landscape
Compared with earlier-stage biotech names, Alnylam sits closer to the commercial-platform side of the landscape, where both launch quality and pipeline renewal matter.
Why the stock is moving
ALNY is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.